Investing.com - Financial Markets Worldwide
🤑 It doesn’t get more affordable. Grab this 60% OFF Black Friday offer before it disappears…CLAIM SALE

Late-stage study of Bristol-Myers' Opdivo/Yervoy combo in poor-risk kidney cancer patients shows mixed results; shares dip 2% after hours

Published 08/15/2017, 04:50 PM
© Reuters. Late-stage study of Bristol-Myers' Opdivo/Yervoy combo in poor-risk kidney cancer patients shows mixed results; shares dip 2% after hours
PFE
-
BMY
-
  • A Phase 3 clinical trial, CheckMate-214, assessing the combination of Bristol-Myers Squibb's (NYSE:BMY) Opdivo (nivolumab) and Yervoy (ipilimumab) compared to sunitinib ( Pfizer (NYSE:PFE)'s Sutent) in intermediate- and poor-risk patients with advanced/metastatic renal cell carcinoma met one co-primary endpoint but missed another.
  • Patients receiving the combination experienced a statistically significantly higher response rate compared to sunitinib (41.6% vs. 26.5%). Progression-free survival favored the combination (11.56 months vs. 8.38 months) but the difference was not statistically valid. Mean duration of response had not been reached in the combination cohort (18.17 months for the sunitinib group).
  • The study will continue as planned to allow the third co-primary endpoint to mature.
  • According to ClinicalTrials.gov, the estimated primary completion date is June 2019.
  • Shares are down 2% after hours on robust volume.
  • Now read: Bristol-Myers - Adding To The Pipeline With IFM


Original article

Latest comments

Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.